LesothoTuberculosis profile
Population  2016 2.2 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.1 (0.56–1.8) 49 (26–80)
Mortality (HIV+TB only) 5.2 (3.3–7.7) 238 (148–350)
Incidence  (includes HIV+TB) 16 (10–23) 724 (468–1 030)
Incidence (HIV+TB only) 12 (7.3–17) 525 (332–760)
Incidence (MDR/RR-TB)** 1.1 (0.71–1.4) 49 (32–66)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 1.1 (0.67–1.5) 5 (3–7) 6.1 (3.7–8.5)
Males 1.2 (0.75–1.7) 8.6 (5.2–12) 9.9 (6–14)
Total 2.3 (1.4–3.3) 14 (8.3–19) 16 (10–23)
TB case notifications, 2016  
Total cases notified 7 513
Total new and relapse 7 291
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 91%
          - % pulmonary 89%
          - % bacteriologically confirmed among pulmonary 56%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 46% (32–71)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.41 (0.21–0.63)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 4 949 73%
          - on antiretroviral therapy 4 243 86%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  410
(330–490)
Estimated % of TB cases with MDR/RR-TB 4.8% (3.7–5.9) 14% (9.2–18)  
% notified tested for rifampicin resistance      
MDR/RR-TB cases tested for resistance to second-line drugs    
Laboratory-confirmed cases MDR/RR-TB: , XDR-TB:
Patients started on treatment **** MDR/RR-TB: 238, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 74% 7 557
Previously treated cases, excluding relapse, registered in 2015 64% 299
HIV-positive TB cases registered in 2015 77% 5 988
MDR/RR-TB cases started on second-line treatment in 2014 64% 152
XDR-TB cases started on second-line treatment in 2014    
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions) 4.7
Funding source: 17% domestic, 67% international, 16% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-17 Data: www.who.int/tb/data